Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026

뉴스 본문을 불러오고 있어요.

Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026 | 웨이프 WAPE

Beam Therapeutics To Present Updated Clinical Data From Phase 1/2 Trial Evaluating BEAM-302 For Alpha-1 Antitrypsin Deficiency At ERS Congress 2026

기사 요약

관련 종목

댓글 —